David, you, our QX everyone and to XXXX call. welcome Thank
launch in pleased on We progress you November the first the XXXX, and the which review saw X subsequent with very today approvals products to of are QX company’s preparations.
progress update the with to on well to you happy as today product the launch We’re respect our as pipeline.
Viret, Our QX financial review questions. to Jean then company’s performance CFO, happy our will your and we’ll take be
per the pleased say executing to launch to UDENYCA that I’m respect launch, are with plan. Now the we
billing logistics proceeding our and are are product expectations UDENYCA. sales, meet and shipping We’re fully the treated smoothly. customers, processes patients being with fulfillment Overall, and
market. successfully of high Coherus Neulasta. remind UDENYCA guaranteed services you, XX% we list projections of is aligned is value quality product, the some with attractive offering believe the that To as comprised initial internal a are We our below robust pleased such and that to have of we a that pricing price and significant Complete supply, presented performance our
patients. implemented and and is providers, the see and long note, just meets our healthcare hospitals in value it On had want bringing recently the held the I that system. needs that to-date to to UDENYCA throughout payers confirms to offering to vision our that gratifying several experience I say a thoughts Our of personal clinics now immensely the visit the and the value country now observed oncology field. firsthand opportunity is
a Let with me our make few to supply. comments respect
for guidance, previous stock per As scenarios. any our even on center period competitive under fulfill XXXX to ample demand our hand an has logistics our highest sufficient extended expected
in UDENYCA earlier dating pegfilgrastim outlined is outpatient As Hospital may consistent strategy patients Hospital live, in biosimilar you recall, oncology segments; of UDENYCA with outpatient we facilities. launch been non-XXXB has and longest has three the months XX U.S. that in XXXB any approved market. broad-based clinics, by the shelf provider our all This utilized XXXX.
previous in respect Medicare with our To-date, on Anthem, as rejected both to among to Now focused coverage issue of payers know, both you previous biologic or XX% reference all claims with better guidance, and biosimilar insurers been level. at as To national payer the including over and recall. major such and any payers as knowledge, United an we launches the securing parity no has was have coverage UDENYCA regional particularly the on there may in from Neulasta which insurers unpaid you Aetna. national our or commercial
value, to to interesting policies have and pricing comparative payers prefer given over is note some Finally, UDENYCA biosimilars Neulasta. UDENYCA including adopted it attractive that
in to to Complete services the early our patient we launched access Coherus patient provider in UDENYCA. offering support January side, Now full
are deliver been uninsured coding Coherus reimbursement, to report very well patients pleased and the with as at all and to supporting already With Complete We provided our am systems, being utilized has charge. with patients mission Coherus that UDENYCA customer is have well inquiries customer that to and all in I resourced we we note am anticipated Coherus of the underinsured no positive to services very have market. to medical patient I demand. assistance. response savings accommodate consistent requests service pleased our very as requests, co-pay information healthcare for And improve from access, offering
few let respect Now me in a make to remarks the adoption with sales.
intake As best we holistic I say, considers should the – individual that and market way a nourish each the conversion. you to launch for know, prior was support branded stakeholder which the expected approach of needs and market biosimilar uptake,
are months expectations approach. and launch, post experience those been with only two we about While consistent this validated our to-date has
early today, to performance initial strategy provide report with pleased on in to first call we launch in not broad our across all our to our aligned of sales. sales course report we’ll look We respect metrics projections we you is updating May plan well our are forward segments. to when QX our with While that quarter internal
while And launch me the few developments I want a let UDENYCA point remarks the Now interest, respect primary the in I to to out with a make is there. things the just of understand pipeline. terms few
biosimilar First, CHS-XXXX. I’ll adalimumab discuss
with reported and now prioritize our and will date this for As our consistent sequence with efforts product BLA settled launch launch date. we have AbbVie a accordingly we earlier, negotiated for XXXX in late
our it’s ourselves. guided, and CHS-XXXX intent As we strategy biosimilar launch have Humira previously our to
oncology will We to anti-TNF the be highly space. infrastructure investment from our expect learnings relevant
that are in will and services relationships patient space direct find payer in we’re anti-TNF the important the the particularly example, space and Coherus applicability. For by the delivered building Complete
service-oriented bill that biosimilar, the market we system the have as dynamic ophthalmology respect similar. very Lucentis continue and buy the potential per oncology to biosimilar, and this savings as Eylea in cost approach as are with our we well Now to applicability CHS-XXXX, that in direct We will efforts CHS-XXXX, our advance to our pursuing branded franchise ophthalmology are plan. believe
with during respect pipeline the to Q&A. We’re happy to in any launch take the questions our
things Viret, company’s Financial who Chief the me will Dr. JV? let turn financials. Now the over Officer, cover to Jean
